Granted Patent B2

US 12,377,113 · App. 18/535,652 · Granted Aug 5, 2025

Inventors: Geoffrey A. von Maltzahn (Boston, MA); Yvonne J. Yamanaka (Cambridge, MA); Jared Silverman (Brookline, MA); John Miles Milwid (Cambridge, MA); Jacob Rosenblum Rubens (Cambridge, MA); John M. Geremia (Watertown, MA)

Assignee: DSM Nutritional Products, LLC

A61K31/702A23L33/125A23L33/135A61K31/716A61K31/733A61K35/741A61K45/06A61P1/00A61P3/02A61P35/00A61P35/04A61P43/00A23V2002/00

Abstract

Claims (21)

1. A method for treating dysbiosis of the gastrointestinal microbiota in a subject having cancer, comprising administering to the subject an effective amount of a composition comprising a glycan therapeutic preparation, wherein:

i) the glycan therapeutic preparation comprises branched glycans comprising glucose, galactose, arabinose, mannose, fructose, xylose, fucose, or rhamnose glycan units;

ii) the glycan therapeutic preparation comprises an average degree of branching (DB) of at least 0.01;

iii) at least 50% of the glycans in the glycan therapeutic preparation have a degree of polymerization (DP) of at least 3 and less than 30 glycan units; and

iv) the ratio of alpha to beta-glycosidic bonds present in the glycans of the glycan therapeutic preparation is between about 1:1 to about 5:1; thereby treating dysbiosis.

2. The method of claim 1 , wherein the method further comprises administering to the subject an anti-cancer agent.

3. The method of claim 1 , wherein the combination is administered to a subject that has been previously treated for cancer.

4. The method of claim 1 , wherein the combination is administered to a subject that has not previously been treated for cancer.

5. The method of claim 2 , wherein the anti-cancer agent comprises a checkpoint inhibitor, a cancer vaccine, an anti-cancer biologic, or a chemotherapeutic agent.

6. The method of claim 5 , wherein the checkpoint inhibitor comprises a targeted kinase inhibitor, a chemotherapeutic, an antibody, an antibody-drug conjugate, a fusion protein, or a small molecule.

7. The method of claim 5 , wherein the cancer vaccine comprises a tumor cell vaccine, an antigen vaccine, a dendritic cell vaccine, a DNA vaccine, or a vector-based vaccine.

8. The method of claim 5 , wherein the checkpoint inhibitor is anti-PD-1, anti-PD-L1, anti-CTLA4, anti-TIM-3 or anti-LAG-3.

9. The method of claim 1 , wherein the composition further comprises a probiotic microorganism.

10. The method of claim 1 , wherein the level of a short-chain fatty acid (SCFA) is increased in the subject upon administration of the composition.

11. The method of claim 10 , wherein the SCFA is one or more of acetate, propionate, and/or butyrate.

12. The method of claim 1 , wherein administration of the composition results in the stimulation of growth or stimulation of activity of beneficial gut bacteria.

13. The method of claim 12 , wherein administration of the composition results in the stimulation of growth or stimulation of activity of Bacteroidetes, Prevotella, Ruminococcus, Parabacteroides , Firmicutes, Alistipes , Lachnospiraceae, and/or Ruminococcaceae.

14. The method of claim 1 , wherein the dysbiosis causes or amplifies the drug- or treatment-induced symptoms, selected from drug toxicities and digestive abnormalities.

15. The method of claim 14 , wherein the drug- or treatment-induced symptoms are reduced in the subject upon administration of the composition.

16. The method of claim 14 , wherein the drug toxicities and digestive abnormalities comprises diarrhea.

17. The method of claim 1 , wherein the subject has an immune imbalance.

Assignments (9)

Continuity (13)

References Cited (297)

Cited By (1)

US 12,508,274